HC Wainwright Has Negative Forecast for OLMA FY2026 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of Olema Pharmaceuticals in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($2.25) per share for the year, down from their prior estimate of ($2.23). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ FY2027 earnings at ($2.32) EPS, FY2028 earnings at ($1.98) EPS, FY2029 earnings at ($1.56) EPS and FY2030 earnings at ($0.83) EPS.

Several other research firms also recently issued reports on OLMA. The Goldman Sachs Group decreased their price objective on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. JPMorgan Chase & Co. boosted their target price on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. Citigroup upped their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wolfe Research started coverage on Olema Pharmaceuticals in a research report on Friday, March 27th. They issued a “peer perform” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Tuesday, April 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.10.

Olema Pharmaceuticals Trading Down 2.8%

NASDAQ:OLMA opened at $13.58 on Thursday. Olema Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $36.26. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -6.72 and a beta of 2.05. The company has a quick ratio of 9.95, a current ratio of 9.95 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $15.79 and its 200-day moving average is $20.45.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its stake in shares of Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares during the period. Torren Management LLC acquired a new stake in Olema Pharmaceuticals during the fourth quarter worth about $44,000. Russell Investments Group Ltd. bought a new position in Olema Pharmaceuticals during the third quarter valued at about $53,000. American Century Companies Inc. acquired a new position in Olema Pharmaceuticals in the 2nd quarter valued at approximately $54,000. Finally, Creative Planning acquired a new position in Olema Pharmaceuticals in the 2nd quarter valued at approximately $83,000. Institutional investors own 91.78% of the company’s stock.

Insider Transactions at Olema Pharmaceuticals

In related news, insider Shawnte Mitchell sold 25,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 12.56% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.